Abstract
Total laryngectomy （TL） had been performed in principle for our patients with clinical T3 （cT3） laryngeal cancer until 2013. The 3-year disease-specific survival rate （DSS） was 100％, which was a good result. However, the laryngeal preservation rate （LPR） was 20.5％, which was substantially lower than that in other institutions. So, in 2014 we started concurrent chemoradiotherapy with cisplatin （CCRT） or radiotherapy with cetuximab （BRT） for patients with cT3 laryngeal cancer as treatment for laryngeal preservation. In principle, patients with paraglottic space invasion without laryngeal fixation are treated with CCRT or BRT, and patients with laryngeal fixation are treated with TL. Of the 20 patients included in this study, 9, 2 and 9 were treated with CCRT, BRT and TL, respectively. There were 2 patients with local control failure, and both were treated with BRT. The 3-year DSS of the CCRT/BRT group and the TL group was 90.0％ and 100％, respectively, showing no significant difference （p＝0.44）. The 3-year LPR of cT3 laryngeal cancers was 50.0％, which was remarkably improved compared with our previous rate. CCRT is an effective treatment for laryngeal preservation for patients with cT3 laryngeal cancer.
